广州白云山医药集团股份有限公司于2024年7月22日晚间发布了一则公告，披露了公司董事长李楚源的辞职报告。公告显示，李楚源因个人原因，决定辞去公司第九届董事会董事长、执行董事以及董事会战略发展与投资委员会主任的职务。公告中还特别强调，李楚源确认与公司董事会之间并无任何意见分歧，且在辞职后，他将不再担任公司的任何职务。
广州白云山医药集团股份有限公司董事会在收到李楚源的辞职报告后，立即进行了内部调整。根据《公司法》和《公司章程》的相关规定，李楚源的辞职并未影响董事会的正常运作，其辞职报告自送达董事会之日起立即生效。公告中还明确指出，李楚源并未直接或间接持有公司股份。
为了确保公司运营的平稳过渡，董事会经过审议后，同意由公司副董事长杨军暂代履行董事长职责。这一任命自董事会通过之日起生效，直到公司选举产生新的董事长。广州白云山医药集团股份有限公司表示，将按照法定程序及时进行董事的补选及新任董事长的选举。
此次董事长的变动，无疑引起了市场及公众的广泛关注。广州白云山作为一家在医药领域具有重要影响力的公司，其领导层的变动，不仅关系到公司的内部治理，也可能会对公司的战略规划和未来发展产生影响。广州白云山医药集团股份有限公司将如何应对这一变动，以及如何确保公司的稳定发展，无疑成为了市场及公众关注的焦点。
英语如下：
News Title: “Li Chuyuan, Chairman of Guangzhou Baiyunshan Pharmaceutical, Resigns for Personal Reasons”
Keywords: Guangzhou Baiyunshan Pharmaceutical, Chairman Resignation, Li Chuyuan
Content: Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced on the evening of July 22, 2024, disclosing the resignation letter of its Chairman, Li Chuyuan, due to personal reasons. The announcement revealed that Li Chuyuan has decided to step down from his positions as Chairman of the Ninth Board of Directors, Executive Director, and Chairman of the Strategic Development and Investment Committee. The announcement emphasized that there are no disagreements between Li Chuyuan and the board of directors, and after his resignation, he will no longer hold any position in the company.
Upon receiving Li Chuyuan’s resignation letter, the board of directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. immediately made internal adjustments. According to the provisions of the Company Law and the company’s articles of association, Li Chuyuan’s resignation did not affect the normal operation of the board. His resignation letter took effect immediately upon delivery to the board. The announcement also clearly stated that Li Chuyuan did not directly or indirectly hold any shares in the company.
To ensure a smooth transition in company operations, the board of directors, after deliberation, agreed to temporarily assign the duties of Chairman to the vice chairman, Yang Jun. This appointment took effect immediately after the board’s approval and will remain in place until a new chairman is elected. Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. stated that it will promptly conduct the election of new directors and the election of a new chairman in accordance with legal procedures.
The change in the chairman has undoubtedly attracted widespread attention from the market and the public. As a company with significant influence in the pharmaceutical industry, changes in its leadership not only affect the company’s internal governance but may also have implications for its strategic planning and future development. How Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. will respond to this change and ensure the stability of its development has become a focus of market and public interest.
【来源】http://www.chinanews.com/cj/2024/07-22/10255415.shtml
Views: 1